Can a protein replacement tame a rare Blood-Clotting disorder?
NCT ID NCT06590974
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This study looks at how well a medicine called Ceprotin (TAK-662) works and how safe it is for people with congenital protein C deficiency, a rare inherited condition that raises the risk of dangerous blood clots. Participants receive the medicine through an IV as part of their usual care, and researchers track any side effects and how effective it is over up to 24 months. The goal is to gather real-world information on this treatment in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Freeze-dried Human Protein C Concentrate (TAK-662) given by intravenous injection
- What this could lead to
- If successful, this could support the safe use of protein C concentrate to manage congenital protein C deficiency, potentially reducing the risk of dangerous blood clots.
- What could go wrong
- This is a small, observational study in Japan with only 7 participants, so results may not apply broadly. As with any blood product, there is a risk of allergic reactions or other adverse events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROTEIN C DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan